Recent advances in the treatment of chronic hepatitis B: where to start initial therapy?
https://doi.org/10.22625/2072-6732-2011-3-4-18-25
Abstract
This review summarizes recent advances in the study of the efficacy and safety of antiviral therapy in patients with chronic hepatitis B. Describe the modern concept of monitoring and treatment of these patients. Particular attention is given to determine the prognostic significance of the level of control HBsAg phases of treatment. Present new algorithms of interferon treatment and approaches nukleos(t)ide analogues therapy. Proposed start initial therapy in patients with chronichepatitis B with pegylated interferon. In the absence of favorable prognostic criteria or sustainable immune control, as well as the presence of contraindications tointerferon therapy and the development of adverse events requiring its withdrawal, patients should be translatedinto treatment nukleos(t)ide analogues.
About the Author
K. V. Zhdanov
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
References
1. EASL Clinical Practice Guidelines: management of chronic hepatitis B. European Association For The Study Of The Liver // J. Hepatol. – 2009. – V. 50, № 2. – P. 227–242.
2. Lampertico, P. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24- onth interferon therapy / P. Lampertico [et al.] // Hepatology. – 2003. – V. 37, № 4. – P. 756–763.
3. Moucari, R. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study / R. Moucari [et al.] // J. Hepatol. – 2009. – V. 50, № 6. – P. 1084–1092.
4. Lin, S.M. Interferon therapyin HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma / S.M. Lin [et al.] // J. Hepatol. – 2007. – V. 46, № 1. – P. 45–52.
5. Marcellin, P. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B / P. Marcellin [et al.] // N. Engl. J. Med. – 2004. – V. 351. – P. 1206–1217.
6. Lau, G.K. Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B /G.K. Lau [et al.] // N. Engl. J. Med. – 2005. – V. 352, № 26. – P. 2682–2695.
7. Janssen, H.L. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial / H.L. Janssen [et al.] // Lancet. – 2005. – V. 365, № 9454. – P. 123–129.
8. Chan, H.L. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferonalpha2b and lamivudine with lamivudine alone / H.L. Chan [et al.] // Ann Intern Med. – 2005. – V. 142, № 4. – P. 240–250.
9. Wong, V.W. How Durable Is Peginterferon Therapy in Hepatitis B e Antigen–Positive Patients? / V.W. Wong //Hepatology. – 2010. – Vl. 51. – P. 1945
10. Buster, E.H. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b / E.H. Buster [et al.] // Gastroenterology. – 2008. – V.135, № 2. – P. 459–467.
11. Marcellin, P. Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a / P. Marcellin [et al.] //Gastroenterology. – 2009. – V.136, № 7. – P. 2169–2179. – E. 1–4.
12. Buster, E.H. Factors that Predict Response of Patients with Hepatitis Be Antigen-Positive Chronic Hepatitis B to Peginterferon-alpha / E.H. Buster [et al.] // Gastroenterology. – 2009. – V. 137, № 6. – P. 2002–2009.
13. Нурмухаметова, Е.А. Генотипы вируса гепатита В: потенциальное клиническое значение / Е.А. Нурмухаметова, Н.П. Блохина // Фарматека. – 2008. – Т. 156, № 2. – С. 33–35.
14. Lampertico, P. PEGBELIVER STUDY: HBsAg decline at week 24 of extendet peginterferon alfa-2a (PEG-IFNα-2a) therapy is significantly associated with post-treatment response in HBeAg-negative genotipe D patients / P. Lampertico [et al.] // J. Hepatol. – 2011. – V. 54 (suppl. 1), – P. S293.
15. Rijckborst, V. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis В using HBsAg and HBV DNA levels / V. Rijckborst [et al.] // Hepatology. – 2010. – V. 52. – P 454–461.
16. Brunetto, M.R. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B / M.R. Brunetto [et al.] // Hepatology. – 2009. – V. 49, № 4. – P. 1141–1150.
17. Moucari, R. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients / R. Moucari [et al.] // Hepatology. – 2009. – V. 49, № 4. – P. 1151–1157.
18. Piratvisuth, T. On-treatment decline in serum HBsAg levels predicts sustained immune control 6 months posttreatment and subsequent HBsAg clearance in HBeAg-positive hepatitis B virus-infected patients treated with peginterferon alfa-2a [40KD] (PEGASYS) / T. Piratvisuth [et al.] //Hepatol Int. – 2010. – V. 4. – P. 152, abstract PP211.
19. Gane, E. NEPTUNE STUDY: on-treatment HBsAg level analysis confirms prediction of response observed in phase 3 study of peginterferon ALFA-2a IN HBeAg-positive patients / E. Gane [et al.] // J. Hepatol. – 2011. – In Press.
20. Marcellin P. On-treatment decline in serum HBsAg levels predicts sustained immune control 6 months post-treatment and subsequent HBsAg clearance in HBeAg-negative hepatitis B virus-infected patients treated with peginterferon alfa-2a [40KD] (PEGASYS) / P. Marcellin [et al.] //Hepatol Int. – 2010. – V. 4. – P. 151, abstract PP209.
21. Rijckborst, V. Early prediction of sustained response to peginterferon alfa-2a in HBeAg-negative patients: the role of on-treatment HBsAg and HBV DNA levels. / V. Rijckborst [et al.] // J. Hepatol. – 2010. – V. 52, suppl. 1. – P. A8
22. Milan, J. Chronic hepatitis B: peginterferon or nucleos(t) ide analogues / J. Milan, L.A. Janssen // Liver Int. – 2011. – V. 31 (supl.1). – P. 78–84.
23. Moucari, R. Peginterferon for chronic hepatitis B: predicting success with on-treatment benchmarks. / R. Moucari // Gastroenterol Hepatol. – 2010. – V. 25. – P. 1474–1475.
24. Moucari, R. Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B / R. Moucari, P. Marcellin // Liver Int. – 2011. – V. 31 (supl. 1). – P.122–128.
25. Sonneveld, M.J. Prediction of sustained response to peginterferon alfa-2b for hepatitis В e antigen-positive chronic hepatitis В using on-treatment hepatitis В surface antigen decline / M.J. Sonneveld [et al.] // Hepatology. – 2010. – V. 52. – P. 1251–1257.
26. Chang, T.T. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B; BEHoLD AI463022 Study Group / T.T. Chang [et al.] // N. Engl. J. Med. – 2006. – V.354, № 10. – P. 1001–1010.
27. Lai, C.L. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B; BEHoLD AI463027 Study Group / C.L. Lai [et al.] // N. Engl. J. Med. – 2006. – V. 354, № 10. – P. 1011–1020.
28. Gish, R.G. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B / R.G. Gish //Gastroenterology. – 2007. – V. 133. – P. 1437–1444.
29. Lai, C.L. Telbivudine versus lamivudine in patients with chronic hepatitis B / C.L. Lai, E. Gane , Y.F. Liaw и соавт. // N. Engl. J. Med. – 2007. – V. 357. – P. 2576–2588.
30. Liaw, Y.F. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B; GLOBE Study Group / Y.F. Liaw [et al.] // Gastroenterology. – 2009. – V. 136, № 2. – P. 486–495.
31. Zeuzem, S. Baseline characteristics and early ontreatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B / S. Zeuzem [et al.] // J. Hepatol. – 2009. – V. 51, № 1. – P. 11–20.
32. Hou, J. Five-year telbivudine treatment with effective viral suppression results in resolution of liver inflammations and fibrosis regression in patients with chronic hepatitis B / J. Hou [et al.] // J. Hepatol. – 2011. – V. 54 (suppl. 1), – P. S287.
33. Heathcote, E.J. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. / E.J. Heathcote [et al.] // Gastroenterology. – 2011. – V. 140, № 1. – P. 132–143.
34. Marcellin, P. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B / P. Marcellin [et al.] // N. Engl. J. Med. – 2008. – V. 359, № 23. – P. 2442–2455.
35. Piratvisuth, T. 1-Year Results of Telbivudine Roadmap Study Demonstrated MaximizingAntiviral Efficacy and Minimizing Resistance in HBeAg Positive Chronic Hepatitis B Patients / T. Piratvisuth [et al.] // Hepatol. Int. – 2011. - V. 5, № 1. – P. 18–19
36. Shouval, D. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy / D. Shouval [et al.] // J. Hepatol. – 2009. – V. 50, №2. – Р. 289–295.
37. Liaw, Y. Impact of hepatitis B therapy on the long-term outcome of liver disease / Y. Liaw // Liver Int. – 2011. – V. 31 (supl. 1). – P. 117–121.
38. Liaw, Y.F. Lamivudine for patients with chronic hepatitis В and advanced liver disease / Y.F. Liaw, J.J.Y. Sung // N Engl. Med. – 2004. – V. 351. –P. 1521–1531.
39. Dienstag, J.L. Histological outcome during long-term lamivudine therapy / J.L. Dienstag [et al.] // Gastroenterology. – 2003. – V. 124. – P. 105–117.
40. Hadziyannis, S.J. Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years / S.J. Hadziyannis [et al.] // Gastroenterology. – 2006. – V.131, № 6. – P. 1743–1751.
41. Marcellin, P. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis В е antigen-positive chronic hepatitis B / P. Marcellin [et al.] // Hepatology. – 2008. – V. 48. – P. 750–758.
42. Yokosuka, O. Long-term use of entecavir in nucleosidenaive Japanese patients with chronic hepatitis В infection / O. Yokosuka [et al.] // Hepatol. – 2010. – V. 52. –P. 791–799.
43. Chang, T.T. Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in chronic hepatitis В patients / T.T. Chang [et al.] // Hepatology. – 2010. – V. 52. – P. 886–893.
44. Heathcote, E.J. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B / E.J. Heathcote [et al.] // Gastroenterology. – 2011. – V. 140, № 1. – P. 132–143.
45. Zoutendijk, R. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss./ R. Zoutendijk [et al.] // J. Infect. Dis. – 2011. – V. 204, № 3. – P. 415–418.
46. Rajendra, A. Economics of chronic hepatitis B and hepatitis C / A. Rajendra, J.B. Wong // J . Hepatol. – 2007. –V. 47, № 4. – P. 608–617.
47. Chevaliez, S. Virological characteristics of a large prospective cohort of patient with chronic hepatitis B newly seen in hepatology reference centers in France in 2008–2010 / S. Chevaliez [et al.] // J. Hepatol. – 2011. – V. 54 (suppl. 1), – P. 146
48. Wursthorn, K. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients / K. Wursthorn [et al.] // Hepatology. – 2010. – V. 52, № 5. – P. 1611–1620.
Review
For citations:
Zhdanov K.V. Recent advances in the treatment of chronic hepatitis B: where to start initial therapy? Journal Infectology. 2011;3(4):18-25. (In Russ.) https://doi.org/10.22625/2072-6732-2011-3-4-18-25
Views:
647
.png)
.png)
Email this article 